Ignite Creation Date:
2024-05-05 @ 9:57 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002620
Status:
COMPLETED
Last Update Posted:
2012-07-02
First Post:
1999-11-01
Brief Title:
Radiation Therapy in Treating Patients With Brain Cancer
Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Organization:
European Organisation for Research and Treatment of Cancer - EORTC
Study Overview
Official Title:
EFFECT OF DIBROMODULCITOL PLUS BCNU ON FREE INTERVAL AND SURVIVAL OF PATIENTS WITH SUPRATENTORIAL MALIGNANT BRAIN GLIOMAS A PHASE III TYPE STUDY
Status:
COMPLETED
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for patients with anaplastic astrocytomas
PURPOSE Randomized phase III trial to study the effectiveness of radiation therapy in treating patients with anaplastic astrocytomas
PURPOSE Randomized phase III trial to study the effectiveness of radiation therapy in treating patients with anaplastic astrocytomas
Detailed Description:
OBJECTIVES I Compare the disease-free interval and survival in patients with supratentorial malignant brain gliomas randomized to radiotherapy alone vs radiotherapy plus radiosensitization with mitolactol DBD followed by DBD and carmustine
OUTLINE Randomized study Group I Radiotherapy External-beam cranial irradiation with megavoltage equipment Group II Radiotherapy with Radiosensitization followed by Maintenance Chemotherapy Radiotherapy as in Group I with Mitolactol DBD NSC-104800 followed by DBD Carmustine BCNU NSC-409962
PROJECTED ACCRUAL A total of 212 patients will be entered over more than 3 years
OUTLINE Randomized study Group I Radiotherapy External-beam cranial irradiation with megavoltage equipment Group II Radiotherapy with Radiosensitization followed by Maintenance Chemotherapy Radiotherapy as in Group I with Mitolactol DBD NSC-104800 followed by DBD Carmustine BCNU NSC-409962
PROJECTED ACCRUAL A total of 212 patients will be entered over more than 3 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EORTC-26882 | None | None | None |